Compare Medline Inc. Class A Common Stock (MDLN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medline Inc. Class A Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Medline Inc. Class A Common Stock trades at $36 (market cap $31.54B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: Medline Inc. Class A Common Stock is far larger — about 4.3× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Medline Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medline Inc. Class A Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MDLN | SYRE | |
|---|---|---|
Market Cap | $31.54B | $7.35B |
Volume | 4,637,232 | 1,624,631 |
Sector | Health | Health |
52-Week High | $49.99 | $108.92 |
52-Week Low | $31.64 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $41.50B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medline (MDLN) trades at $35.70, down 0.17% with a bullish technical outlook despite recent volatility. The company shows strong revenue growth with $28.43B in 2025 and improved earnings beats in Q1-Q2 2026. However, multiple securities fraud investigations related to product quality issues and a 13% stock drop in October 2026 create significant headwinds. Analyst consensus remains strongly bullish with 88% buy ratings and a $44.11 price target, representing 23.6% upside potential from current levels.
MDLN presents a high-risk, high-reward opportunity with strong fundamentals offset by legal uncertainties. The stock's valuation appears reasonable with P/E of 44.66 and P/S of 1.05, while technical indicators suggest near-term support at $35. Key risks include ongoing fraud investigations and potential legal liabilities that could impact future performance despite positive earnings momentum.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
